Oral squamous cell carcinoma (OSCC) is the most common tumour of the feline oral cavity and is associated with devastating outcomes. Similar to human OSCC, Cyclooxygenase 2 (COX-2) expression and prostaglandin E2 (PGE2) synthesis have been demonstrated in feline OSCC (FOSCC). CD147, a known mediator of invasive behaviour, was also shown to be expressed in FOSCC. Other elements of the arachidonic acid pathway of inflammation, including microsomal and cytosolic PGE2 synthase enzymes (mPGES1, mPGES2 and cPGES) and PGE2 receptors (EP1-EP4), have not been investigated in FOSCC. Tumour hypoxia can support growing tumours by stimulating formation of new blood vessels through activity of hypoxia inducible factor 1 alpha (HIF-1α) and expression of vascular and endothelial growth factor type A (VEGFA). In humans, hypoxia impacts radiotherapy treatment and decreases the sensitivity of OSCC to chemotherapy. In human OSCC, expression of p16 is associated with papillomavirus infection and better prognosis. There have been fewer studies of p16 in FOSCC, and none directly comparing p16 expression in FOSCC to human OSCC. The objectives of this research were to investigate gene expression related to PGE2-associated inflammation and angiogenesis in vitro, to explore the relationship between mPGES1 and p16, COX-2, and CD147 in human and feline OSCC tumour samples, and to evaluate the effect of hypoxia on gene expression and cell culture viability resulting from chemotherapy and anti-inflammatory drug treatment. This work demonstrated that FOSCC cell lines express mPGES/cPGES genes (PTGES1-3) and EP receptor genes (PTGER1-4) to varying degrees, as well as genes encoding HIF-1α and VEGFA. Gene expression in FOSCC cells (SCCF2) was altered by exogenous PGE2 exposure, and EP4 antagonism resulted in varying responses suggesting that EP4 deserves further study in FOSCC. In biopsy samples of human and feline OSCC, immunohistochemistry (IHC) revealed that a subset of tumours expressed mPGES1 and p16. High CD147 expression was more common in high mPGES1 tumours in both species, though only reached statistical significance in the human samples. High p16 tumours were more common in the human oropharynx compared to the oral cavity, as expected given the importance of papillomavirus infection in the pathogenesis of human OSCC at this location. No significant difference in p16 expression between tongue and non-tongue tumours was observed in FOSCC. In vitro, 4 hours of hypoxia stimulated expression of PTGES1 (mPGES1). Interestingly, hypoxia reduced the sensitivity of SCCF2 to cytotoxic drugs (doxorubicin and carboplatin) but not to a cyclooxygenase inhibitor (piroxicam) or an EP4 inhibitor. Interestingly, hypoxia increased the antiproliferative effect of an mPGES1 inhibitor in SCCF2 cells. Collectively, these studies indicate mPGES1 may be an important mediator of inflammation and hypoxic response in FOSCC patients, possibly serving as a therapeutic target and deserving of continued study. Further study is needed in order to determine the role of p16 as a prognostic indicator in FOSCC. Based on p16 expression, it appears that FOSCC may have similarities with non-HPV-associated OSCC in people, which is more often localized to the oral cavity than the oropharynx and has a worse prognosis than HPV-associated tumours. New knowledge related to FOSCC mechanisms and treatment could benefit studies of oral cavity OSCC in people.